Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China

Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China

Acute hepatitis E infection could induce severe outcomes among chronic hepatitis B (CHB) patients. Between 2016 and 2017, an open-label study was conducted to evaluate the immunogenicity and safety of hepatitis E vaccine (HepE) in CHB patients, using healthy adults as parallel controls in China. Eli...

Full description

Saved in:
Bibliographic Details
Main Authors: Li Zhang, Qiufen Zhang, Jiaye Liu, Wenlong Wu, Zechun Jiang, Bingyu Yan, Qingfan Cao, Haidong Liu, Huirong Pan, Jingjing Lv, Yi Feng, Fujie Xu, Shoujie Huang, Aiqiang Xu
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Hepatitis E vaccine
chronic hepatitis B
immunogenicity
safety
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2448882
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2448882

Similar Items